老年急性粒细胞白血病的治疗进展

国际输血及血液学杂志 Pub Date : 2019-11-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.06.011

Di Wu

{"title":"老年急性粒细胞白血病的治疗进展","authors":"Di Wu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.011","DOIUrl":null,"url":null,"abstract":"Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on. \n \n \nKey words: \nLeukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"524-529"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progresses in treatment of elderly patients with acute myeloid leukemia\",\"authors\":\"Di Wu\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.06.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on. \\n \\n \\nKey words: \\nLeukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"524-529\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

老年急性髓细胞白血病（AML）患者由于高危因素比例较高而难以治疗，传统化疗的疗效仍不令人满意。近年来，有关老年AML患者风险分层的研究促使治疗方法的个性化。此外，低甲基化药物（HMA）、新型靶向药物、免疫疗法和造血干细胞移植（HSCT）的改进在提高病情缓解率和生存率的同时降低治疗相关毒性方面显示出了良好的前景，从而为这一特殊人群的诊断和治疗提供了新的方向。本文从分层评价、化疗、HMA、分子靶向治疗、免疫治疗、细胞周期蛋白激酶抑制剂、HSCT等方面综述了老年AML患者治疗进展；老年人；老年评估；脱甲基；分子靶向治疗；免疫治疗；造血干细胞移植

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Progresses in treatment of elderly patients with acute myeloid leukemia

Elderly patients with acute myeloid leukemia (AML) are difficult to treat due to higher proportion of high risk factors and the efficacy of conventional chemotherapy remains unsatisfying. In recent years, researches concerning risk stratification of elderly patients with AML have prompted the individualization of therapeutic approaches. Besides, the advent of hypomethylating agents(HMA), novel targeted drugs, immunotherapy and the improvement of hematopoietic stem cell transplantation (HSCT) have shown promising prospects in elevating remission and survival rates while lowering treatment-related toxicities, thus providing new orientations of the diagnosis and treatment of this special population. This article reviews literatures of progress in the treatment of elderly patients with AML in aspects of stratified evaluation, chemotherapy, HMA, molecular targeted therapy, immunotherapy, cyclin kinase inhibitors, HSCT, and so on. Key words: Leukemia, myeloid, acute; Aged; Geriatric assessment; Demethylation; Molecular targeted therapy; Immunotherapy; Hematopoietic stem cell transplantation

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.